Jazz Pharmaceuticals (JAZZ) Intangibles (2010 - 2026)

Jazz Pharmaceuticals' Intangibles history runs 17 years deep, the most recent figure standing at $4.2 billion for Q1 2026.

• On a quarterly basis, Intangibles fell 10.9% year-over-year to $4.2 billion in Q1 2026; TTM through Mar 2026 was $4.2 billion, a 10.9% decrease from a year earlier, with the FY2025 full-year figure at $4.4 billion, down 6.86% from the prior year.
• Intangibles declined to $4.2 billion in Q1 2026 per JAZZ's latest filing, from $4.4 billion in the prior quarter.
• Across five years, Intangibles topped out at $6.8 billion in Q1 2022 and bottomed at $752.5 million in Q4 2023.
• The 5-year median for Intangibles is $5.1 billion (2024), against an average of $5.0 billion.
• Across the five-year window, Intangibles jumped 556939.4% in 2022 and sank 87.01% in 2023, its largest moves.
• Year by year, Intangibles stood at $5.8 billion in 2022, then sank by 87.01% to $752.5 million in 2023, then surged by 531.99% to $4.8 billion in 2024, then slipped by 6.86% to $4.4 billion in 2025, then dropped by 5.1% to $4.2 billion in 2026.
• Per Business Quant, the three latest JAZZ Intangibles figures stand at $4.2 billion (Q1 2026), $4.4 billion (Q4 2025), and $4.6 billion (Q3 2025).